Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02360397 · ClinicalTrials.gov registry record · Phase 2
Ranolazine Mediated PVC Reduction in Ischemic Heart Disease
A Phase 2 study of Myocardial Ischemia and Ventricular Premature Complexes, sponsored by Kent Hospital, Rhode Island.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT02360397 is a Phase 2 study of Myocardial Ischemia and Ventricular Premature Complexes that has completed, run by Kent Hospital, Rhode Island. The registered enrollment target is 6 participants, below the 2,138-participant average among 29 other Myocardial Ischemia trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02360397, a Phase 2 study of Myocardial Ischemia and Ventricular Premature Complexes, has completed, sponsored by Kent Hospital, Rhode Island.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether ranolazine has beneficial effects on cardiac ischemia through reduction of premature ventricular contraction burden.
Conditions Studied
Interventions
- DRUG ranolazine
Study Locations (1)
Rhode Island
- Kent Hospital - Warwick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-12 |
| Est. Completion | 2018-02-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02360397
The ClinicalTrials.gov registry entry for NCT02360397 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,138-participant average among 29 other Myocardial Ischemia trials with a reported enrollment target (100% lower). The listed sponsor is Kent Hospital, Rhode Island, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Myocardial Ischemia appearing as the primary indexed condition, and to 1 intervention - of which ranolazine is the first listed.
NCT02360397 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.
Frequently Asked Questions
What is clinical trial NCT02360397 about?
NCT02360397 is a clinical study titled "Ranolazine Mediated PVC Reduction in Ischemic Heart Disease". The purpose of this study is to determine whether ranolazine has beneficial effects on cardiac ischemia through reduction of premature ventricular contraction burden.
What is the current status of trial NCT02360397?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2014-12. Estimated completion is 2018-02-23.
What conditions does trial NCT02360397 study?
This clinical trial studies the following conditions: Myocardial Ischemia, Ventricular Premature Complexes.
What interventions are being tested in trial NCT02360397?
The interventions under investigation include: ranolazine (DRUG).
Who is sponsoring clinical trial NCT02360397?
This trial is sponsored by Kent Hospital, Rhode Island, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02360397 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myocardial Ischemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ACT34-CMI -- Adult Autologous CD34+ Cells
COMPLETED · Phase 2
-
Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery
COMPLETED · Phase 2
-
Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent
COMPLETED · Phase 2
-
Nitric Oxide Inhalation Therapy to Relieve Chest Pain in Patients With Coronary Artery Disease
COMPLETED · Phase 2
-
Bright Light Exposure in Surgical Patients
RECRUITING · NA
-
A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.